0.0001USD0.00%Mkt Cap: 139 USDP/E: —Last update: 2026-05-25
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It devel…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap139 USD
Enterprise Value-2.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-32.34M USD
Revenue/Share—
Last Price0.0001 USD
Fiscal Year EndDec 2023
MR QuarterJun 2024
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.15
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)-18.51
EPS (Forward)-3.75
52W Range
0.00010% of range1.010
52W High1.010 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-921.57%
ROA-376.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.43M USD
CapEx (TTM)48.72K USD
FCF Margin—
FCF Yield-5107739.57%
Net Debt-2.42M USD
Net Debt/EBITDA0.15
Balance Sheet
Debt/Equity0.02
Current Ratio0.66
Quick Ratio0.51
Book Value/Sh0.4990 USD
Cash/Share1.738 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateOct 19, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.39M
Float1.18M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio2.3d
Short % Float1.30%
Short % Out.1.17%
Shares Short15.99K
Short (prev mo.)12.32K
Technical
SMA 500.0002 (-35.9%)
SMA 2000.0006 (-82.9%)
Beta3.93
S&P 52W Chg28.31%
Avg Vol (30d)257
Avg Vol (10d)469
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—